In the absence of a drug that can cure or prevent the emerging corona virus infection, the search continues for a drug that can prevent even the most dangerous and severe forms of the disease.
In this context, the pharmaceutical group “AstraZeneca” announced today, Friday, the results of a treatment that can significantly reduce the risk of developing severe forms of Kovid-19 disease and its symptoms.
The drug, which was made from a combination of two antibodies, was initially developed as a treatment for infected people.
AstraZeneca said in a statement that a new study involving 5,197 non-infected participants showed a 77% reduction in symptomatic infections and no serious cases were reported.
A previous test of AZD7442 showed that it only reduced the risk of developing symptoms by 33 percent, and the results are considered statistically insignificant in June.
Data show that a single dose can “quickly and effectively prevent the symptoms of Covid-19”, said lead investigator Merin Levine.
“With these exciting results, this drug could be an important tool in our arsenal, helping people who need more of a vaccine return to their normal lives.”
The group hopes the drug will be used in conjunction with vaccines for people who need more protection, providing immunity for up to 12 months.
The development of the drug was funded by the US government, and the group has agreements to receive 700,000 doses.
The company is now required to send data to health authorities for approval or conditional approval for immediate use.
Promotes the effects of a drug that reduces severe forms of corona
